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Abstract
Background: Non-alcoholic steatohepatitis (NASH) is a serious form of non-alcoholic fatty liver disease (NAFLD), associated
with obesity and insulin resistance. Previous studies suggested that intestinal bacteria produced more alcohol in obese mice
than lean animals.
Methodology/Principal Findings: To investigate whether alcohol is involved in the pathogenesis of NASH, the expression
of inflammation, fibrosis and alcohol metabolism related genes in the liver tissues of NASH patients and normal controls
(NCs) were examined by microarray (NASH, n=7; NC, n=4) and quantitative real-time PCR (NASH, n=6; NC, n=6). Genes
related to liver inflammation and fibrosis were found to be elevated in NASH livers compared to normal livers. The most
striking finding is the increased gene transcription of alcohol dehydrogenase (ADH) genes, genes for catalase and
cytochrome P450 2E1, and aldehyde dehydrogenase genes. Immunoblot analysis confirmed the increased expression of
ADH1 and ADH4 in NASH livers (NASH, n=9; NC, n=4).
Conclusions/Significance: The augmented activity of all the available genes of the pathways for alcohol catabolism suggest
that 1) alcohol concentration was elevated in the circulation of NASH patients; 2) there was a high priority for the NASH
livers to scavenge alcohol from the circulation. Our data is the first human evidence that suggests alcohol may contribute to
the development of NAFLD.
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Introduction
Non-alcoholic steatohepatitis (NASH) is a serious form of non-
alcoholic fatty liver disease (NAFLD), characterized by hepatic
steatosis associated with evidence of inflammation and variable
degrees of fibrosis [1]. The prevalence of NASH is increasing with
the ever-growing problem of obesity in the general population. Up
to 20% of the population may have fatty liver, and up to 3% may
have NASH as estimated in 2004 [2].
According to the current ‘‘two-hit’’ hypothesis, NASH patients
first develop fatty liver before a second hit initiates inflammation in
the liver [3]. Studies with NASH patients and various animal
models in the last decade have revealed insights into liver fat
infiltration, damage, inflammation and fibrosis. Insulin resistance
(IR) seems to be a major reason for fat deposition in liver by way of
uncontrolled lipolysis in adipose tissue leading to increased levels
of circulating free fatty acids [4]. Measurement with stable isotopes
in NAFLD patients indicated that free fatty acids are the major
source for fat accumulation in liver. De novo lipogenesis and
dietary fatty acids are also significant sources of fat [5]. Other
studies suggested that insufficient fatty acid utilization could also
cause fat desposition in hepatocytes. Peroxisome proliferator-
activated receptors are transcriptional factors regulating lipid
metabolism in liver and therefore believed to play a central role in
hepatic fat accumulation [6]. Lipotoxicity may cause mitochon-
drial dysfunction and subsequent liver damage and trigger
inflammation [7]. Oxidative stress is possibly a potent thrust in
this process and in subsequent activation of hepatic stellate cells
[8].
Despite these efforts, the exact mechanism of the development
of NASH is unclear. And it remains a puzzle that NASH and
alcoholic steatohepatitis share many histological features [9]. Both
NASH and alcoholic steatohepatitis patients exhibit macrovesi-
cular and microvesicular fat in hepatocytes. The number and size
of Mallory bodies, and the pattern of pericellular fibrosis are also
indistinguishable between two disease groups. Previous studies
suggested that intestinal bacteria produced more alcohol in obese
mice than lean animals [10]. Therefore, we hypothesize that
alcohol is involved in the pathogenesis of NASH.
In this report, gene expression in NASH livers was examined by
a whole-genome DNA microarray and quantitative real-time PCR
(qRT-PCR). We found that all the available genes of the pathways
for alcohol catabolism exhibited elevated expression levels in
NASH livers, among which the elevated protein levels of ADH1
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9570and ADH4 in NASH livers were confirmed by Western blot
analysis. Our results suggest a key role for intestinal alcohol in the
pathogenesis of NASH.
Methods
Patients
The human studies have been approved by the Institutional
Review Board (IRB) of the State University of New York at
Buffalo. Only children and adolescents were included in this study
to ensure that our patients were not sustained alcohol users. All
NASH patients included in this study (Table 1) exhibited
significant insulin resistance (IR). IR was calculated based on the
‘‘homeostasis model assessment (HOMA)’’ method [11]. Liver
biopsies were obtained, with prior written consent, from parents of
patients suspected of having NASH as part of regular medical
care. Patients from 7 to 18 years of age signed an assent to the
research. Diagnosis of NASH was based on hepatic fat infiltration,
inflammation and fibrosis as revealed by liver biopsy, following
Kleiner’s criteria [12].
For non-steatosis controls, total RNA was purchased from
Admet Technologies (Durham, NC). These samples were
derived from liver grafts of normal controls with normal body
mass index (Table 1). The ages of these normal controls were
similar to our NASH patients. No liver diseases were diagnosed
with these normal controls. The healthy status of these livers
was ascertained by the lower transcription levels of marker
genes for inflammation and fibrosis, as detailed in the Results
section. The non-NASH controls used in Western blot analysis
were liver biopsies from patients with hepatitis C, autoimmune
hepatitis, gall stones or cystic fibrosis, respectively. They were
free from steatosis.
Table 1. Characteristics of study groups.
Microarray Real-time PCR Western blot
NASH Normal control
{ NASH Normal control
{ NASH Non-NASH control
{
Sex (F : M) F2 : M5 F1 : M3 F2 : M3 F2 : M4 F4 : M5 F3 : M1
Age (years) 9–16 1–19 9–14 1–9 11–18 4–12
Body Mass Index 35.062.9
1 19.161.6
" 38.465.9
1 16.560.8
" 32.761.6
1 20.662.9
"
Fasting Insulin (mU/ml) 27.062.2 NA 31.262.3 NA 20.765.1 ,2
Fasting glucose (mmol/L) 5.060.2 NA 5.160.3 NA 5.760.4 4.760.2
IR (HOMA)
{{ 6.060.5 NA 7.060.5 NA 5.761.7 ,1
{Normal healthy liver intended for transplantation, no liver disease reported.
{Liver biopsies from patients with hepatitis C, autoimmune hepatitis, gall stones or cystic fibrosis, respectively. They were free from steatosis.
1Patients are all above 95 percentile of the population.
"Normal controls are all below 80 pencentile of the population.
{{IR (HOMA) for healthy subjects is around 1.
NA: Not available.
doi:10.1371/journal.pone.0009570.t001
Table 2. Primer pairs for real-time quantitative PCR analysis.
Symbol Description Sequence
GAPD glyceraldehyde-3-phosphate dehydrogenase AGCCTCAAGATCATCAGCAATG (Forward)
ATGGACTGTGGTCATGAGTCCTT (Reverse)
CXCL10 chemokine (C-X-C motif) ligand 10 TTCCTGCAAGCCAATTTTGT (Forward)
ATGGCCTTCGATTCTGGATT (Reverse)
ADH1C alcohol dehydrogenase 1C (class I) GGCTTGACACCATGATGGCT (Forward)
GGAGGTACCCCTACAATGACA (Reverse)
ADH4 alcohol dehydrogenase 4 (class II) CTGAAACCATGAAAGCAGCC (Forward)
GCCGATTATTAGCTCCTCTGG (Reverse)
ADH6 alcohol dehydrogenase 6 (class V) CAATACTGCCAAGGTGACTCC (Forward)
GCTCCTGCTGCTTTACAACC (Reverse)
ALDH2 aldehyde dehydrogenase 2 TGGTTACTTCATCCAGCCCAC (Forward)
GCTCTCCCAACAACCTCCTCTAT (Reverse)
ALDH8A1 aldehyde dehydrogenase 8 family, member A1 TGGGAGTCGCTGGTCTGAT (Forward)
CTGGGCTTGGCTATCACAGT (Reverse)
TLR4 toll-like receptor 4 AATCCCCTGAGGCATTTAGG (Forward)
CCCCATCTTCAATTGTCTGG (Reverse)
doi:10.1371/journal.pone.0009570.t002
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Liver biopsies were stored in RNAlater before total RNA was
extracted with RNeasy and treated with RNase-free DNase I set
(Qiagen, Valencia, CA). RNA samples obtained from Admet were
also treated with RNase free DNase before downstream
experiments. Quality of the RNA samples was assured with
Bioanalyzer (Agilent Technologies) before downstream biotin-
labeling and hybridization to the CodeLink Human Whole
Genome Bioarray (GE Health care-Amersham Biosciences,
Piscataway, NJ) following the manufacturer’s manual. The original
microarray data have been uploaded to Gene Expression
Omnibus (GEO) website: http://www.ncbi.nlm.nih.gov/geo/index.
cgi. All data is MIAME compliant. The accession numbers for NASH
liver datasets are GSM435821 to GSM435827, and for normal
control datasets: GSM435828, GSM435833 to GSM435835.
Quantitative RT-PCR
Specific primers (Table 2) were designed with the assistance of
Primer 3 [13]. Complementary DNA was synthesized from 0.8 mgo f
RNA in a volume of 20 ml, using the iScript cDNA synthesis kit (Bio-
Rad Laboratories, Hercules, CA). Real-time PCR was performed on
an iCycler iQ real-time detection system (Bio-Rad Laboratories,
Hercules, CA), using Sybergreen (iQ
TM SYBRH Green Supermix;
Bio-Rad Laboratories, Hercules, CA) for real-time monitoring of the
PCR. GAPD RNA level were tested in parallel with the genes of
interest. The presence of a single specific PCR product was verified
by melting curve analysis and confirmed on agarose gels.
Threshold cycles (Ct) for each sample were determined by Bio-
rad iQ5 optical system software (Bio-Rad Laboratories). The
concentration of mRNA ([mRNA]) is represented by the following
equation: [mRNA]=M/E
Ct, where constant M is an arbitrary
threshold, E is the efficiency of PCR, Ct is the threshold cycle. All
PCR reactions had efficiencies higher than 1.9, as determined
experimentally with 4-times serial diluted samples. The relative
mRNA concentration of each target gene was calculated as the
mRNA concentration of target gene normalized against that of
GAPD, as represented by the following equation:
mRNA ½  target= mRNA ½  GAPD~EGAPD
Ct:GAPD=Etarget
Ct:target
Western Blot Analysis
Liver biopsies stored in RNAlater were homogenized in PBS,
and then boiled for 5 min in SDS-PAGE loading buffer. Samples
Table 3. Comparison of the gene expressions between liver tissues and breast cancer tissues.
{
GenBank
Accession # Gene Description
NASH Liver
(n=7)
Normal Liver
(n=4)
Breast Cancer
(n=4)
NASH Liver/Breast
Cancer
{
NM_000402.2 glucose-6-phosphate
dehydrogenase (G6PD)
1.5860.10
1 1.5360.27 1.3760.64 1.16
NM_001101.2 actin, beta (ACTB) 18.1962.91 16.0764.88 20.38619.35 0.89
NM_000034.2 aldolase A, fructose-bisphosphate
(ALDOA)
9.0261.63 19.0264.34 6.9166.18 1.30
NM_003379.3 villin 2 (ezrin) (VIL2) 1.7860.42 4.0261.28 1.3860.84 1.29
AL133626.1 H2A histone family, member J 1.6660.12 1.8160.22 1.8860.20 0.88
NM_002954.3 ribosomal protein S27a (RPS27A) 171.21646.00 184.38633.35 91.67661.77 1.87
NM_006951.2 TAF5 RNA polymerase II, TATA box
binding protein-associated factor
1.6460.24 1.0460.25 1.4660.20 1.13
NM_001190.1 branched chain aminotransferase
precursor (BCATm)
1.3260.42 1.4060.64 1.4460.39 0.92
NM_000777.2 cytochrome P450, family 3,
subfamily A, polypeptide 5 (CYP3A5)
4.9161.83 8.0863.40 0.0060.21 10177.97
NM_000040.1 apolipoprotein C-III (APOC3) 625.936126.08 312.83667.97 0.4060.00 1579.62
NM_001443.1 fatty acid binding protein 1,
liver (FABP1)
605.55680.67 250.15651.55 0.4260.25 1458.34
NM_000039.1 apolipoprotein A-I (APOA1) 557.21658.12 306.33652.72 0.5260.16 1071.00
NM_006744.2 retinol binding protein 4,
plasma (RBP4)
606.95683.36 295.00643.11 0.6860.30 888.88
NM_145740.1 glutathione S-transferase A1 (GSTA1) 312.50633.64 25.17614.02 0.4260.22 742.18
NM_000667.2 alcohol dehydrogenase 1A (class I),
alpha polypeptide (ADH1A)
470.96640.68 82.50634.30 0.6460.11 735.11
NM_000483.3 apolipoprotein C-II (APOC2) 501.93630.57 288.10649.95 1.2060.75 419.61
NM_000236.1 hepatic triglyceride lipase (HTGL) 289.35647.50 142.52610.06 0.7660.23 383.05
NM_000670.2 alcohol dehydrogenase 4 (class II),
pi polypeptide (ADH4)
257.14638.38 6.5362.17 0.8060.44 323.14
NM_000041.1 apolipoprotein E (APOE) 353.83649.92 258.38653.30 1.8160.63 195.99
{Microarray data for breast cancer were downloaded from PubMed, accession #: GSE6304.
{Fold difference of gene expression levels (sample mean) between NASH liver tissues and breast cancer tissues.
1Median normalized gene expression signal as detected by the Codelink microarray. Sample mean 6 standard error.
"For all the liver specific genes listed, significant differences in gene expression were detected between liver tissues and breast cancer tissues (P,0.05).
doi:10.1371/journal.pone.0009570.t003
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After blotting onto nitrocellulose membranes, ADH1 (cat#sc-
137091, Santa Cruz Biotechnology Inc., CA), ADH4 (cat#sc-
134249, Santa Cruz Biotechnology Inc.) and b-actin (Clone C4,
MP Biomedicals, LLP, Ohio) were probed on separate blots, as all
these proteins are of similar sizes. The results were visualized using
Table 4. Comparison of gene expressions between NASH livers and normal controls: house-keeping genes, inflammation and
fibrosis related genes.
{
GenBank
Accession# Gene Description
NASH Liver
(n=7)
Normal Liver
(n=4)
NASH/
Normal
{
P
value
1
NM_000402.2 glucose-6-phosphate dehydrogenase (G6PD) 1.5860.10 1.5360.27 1.03 0.875
NM_001101.2 actin, beta (ACTB) 18.1962.91 16.0764.88 1.13 0.723
NM_000034.2 aldolase A, fructose-bisphosphate (ALDOA),
transcript variant 1
9.0261.63 19.0264.34 0.47 0.100
NM_003379.3 villin 2 (ezrin) (VIL2) 1.7860.42 4.0261.28 0.44 0.179
AL133626.1 H2A histone family, member J 1.6660.12 1.8160.22 0.91 0.560
NM_002954.3 ribosomal protein S27a (RPS27A) 171.21646.00 184.38633.35 0.93 0.822
NM_006951.2 TAF5 RNA polymerase II,
TATA box binding protein
(TBP)-associated factor
1.6460.24 1.0460.25 1.59 0.122
NM_001190.1 branched chain aminotransferase precursor
(BCATm)
1.3260.42 1.4060.64 0.94 0.922
NM_002121.4 major histocompatibility complex, class II,
DP beta 1 (HLA-DPB1)
70.9468.30 3.4961.96 20.31 0.000
NM_006120.2 major histocompatibility complex, class II,
DM alpha (HLA-DMA)
24.9163.39 4.7761.41 5.22 0.001
NM_002121.4 major histocompatibility complex, class II,
DP beta 1 (HLA-DPB1)
15.8662.85 1.0160.28 15.64 0.002
NM_002127.3 HLA-G histocompatibility antigen,
class I, G (HLA-G)
27.8862.00 7.9760.71 3.50 0.000
NM_019111.2 major histocompatibility complex,
class II, DR alpha (HLA-DRA)
153.26618.42 15.6764.81 9.78 0.000
NM_033554.2 major histocompatibility complex,
class II, DP alpha 1 (HLA-DPA1)
122.95615.12 10.7763.51 11.41 0.000
X02902.1 mRNA for HLA class II DR-beta 1 (Dw14) 26.2965.05 2.0860.74 12.64 0.003
NM_001565.1 chemokine (C-X-C motif) ligand 10 (CXCL10) 26.0466.78 1.2160.47 21.55 0.010
NM_004887.3 chemokine (C-X-C motif) ligand 14 (CXCL14) 62.9768.44 3.7861.79 16.64 0.000
NM_000609.3 chemokine (C-X-C motif) ligand 12
(stromal cell-derived factor 1) (CXCL12)
13.9962.63 2.5661.46 5.47 0.005
NM_005409.3 chemokine (C-X-C motif) ligand 11 (CXCL11) 0.8260.10 0.2760.10 3.08 0.004
NM_001250.3 tumor necrosis factor receptor superfamily,
member 5 (TNFRSF5), transcript variant 1
8.0061.16 1.5760.69 5.08 0.001
NM_000043.3 tumor necrosis factor receptor superfamily,
member 6 (TNFRSF6), transcript variant 1
7.2260.80 2.5960.76 2.79 0.003
NM_000072.1 CD36 antigen (collagen type I receptor,
thrombospondin receptor) (CD36)
16.5563.10 2.8761.63 5.76 0.004
NM_005505.3 CD36 antigen (collagen type I receptor,
thrombospondin receptor)-like 1 (CD36L1)
1.8460.41 0.7660.15 2.42 0.041
NM_030582.2 collagen, type XVIII, alpha 1 (COL18A1),
transcript variant 1
29.3063.83 9.6962.14 3.02 0.002
NM_001853.2 collagen, type IX, alpha 3 (COL9A3) 6.0061.94 1.1560.66 5.20 0.049
NM_004369.1 RNA for type VI collagen alpha3 chain 4.7360.79 1.4160.73 3.36 0.014
X52022.1 RNA for type VI collagen alpha3 chain 1.1060.10 0.2860.17 3.95 0.011
NM_001850.3 collagen, type VIII, alpha 1 (COL8A1),
transcript variant 1
1.5060.15 0.4360.04 3.49 0.000
NM_015719.2 collagen, type V, alpha 3 (COL5A3) 0.9860.26 0.1760.05 5.73 0.019
{The gene expression levels (sample mean 6 standard error) shown were median normalized.
{Fold difference of gene expression levels (sample mean) between NASH liver tissues and normal liver controls.
1Two tailed student t test.
doi:10.1371/journal.pone.0009570.t004
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gen) and recorded with an image reader LAS-1000 (Fujifilm).
Statistical Analysis
All analysis for statistically significant differences was performed
with Student’s t test with a two-tailed distribution. P values smaller
than 0.05 were considered significant.
Results
The Integrity of the Microarray Datasets
To compare the global gene expression profiles between
NASH livers and normal livers, total RNA samples from both
populations (NASH, n=7; NC, n=4) were analyzed on
CodeLink Human Whole Genome Bioarray. To ascertain the
quality of RNA used in microarray analysis, similar datasets of
breast cancer tissue generated with the same CodeLink platform
were downloaded (GEO accession numbers: GSM144855 to
GSM144858) and compared with the liver microarray datasets.
As represented by the housekeeping genes listed in Table 3
(upper part), the majority of the genes showed similar expression
levels among NASH livers, normal livers and breast cancer
tissues. In contrast, drastically elevated expression was detected
in liver tissues for the liver-specific genes including apolipopro-
teins, fatty acid binding protein, hepatic triglyceride lipase,
glutathione S-transferase, and alcohol dehydrogenase (Table 3,
lower part).
Elevated Expression of Inflammation and Fibrosis Related
Genes in NASH Livers
The expression levels of genes involved in the process of
inflammation and fibrosis were of immediate attention, as the
activities of these genes would provide an ultimate evaluation of the
quality of the datasets. Listed in Table 4, most of the chosen
housekeeping genes showed similar transcription levels between
NASH livers and normal controls (Table 4, upper panel). In
contrast, significant differences were observed for many genes known
to be involved in inflammation (Table 4, middle panel). These
include several members of the HLAs, C-X-C motif containing
chemokines and members of the TNF receptor superfamily.
The NASH patients included in this study all had certain
degrees of fibrosis. It was therefore of great interest to see if the
NASH microarray dataset could characterize the disease status.
The abnormal deposition of collagen is a structural basis of liver
fibrosis. From the datasets, it was noted that several types of
collagen and collagen receptor exhibited elevated transcription
activity in NASH livers (Table 4, lower panel). The activation of
stellate cells from their resting state to myofibroblasts was also
suggested by the elevated transcription for genes specific for
smooth muscle functions (data not shown).
To confirm the observations made with the microarray
technique, cDNA was synthesized from liver RNA and subjected
to qRT-PCR analysis (NASH, n=6; NC, n=6) with gene specific
primer pairs for GAPD and CXCL10 (Table 2). CXCL10 was
chosen because it was the most highly activated inflammatory gene
based on the microarray datasets. The real-time PCR result
(Figure 1) indicated that the transcription level of CXCL10 in
NASH liver was 21.86 times of that in normal healthy liver
(P=0.003), which is consistent with the microarray data (in which,
NASH/normal=21.55).
Overall, the elevated transcription of inflammation and fibrosis
related genes validated both the NASH and normal control
samples for further investigation on the gene expression patterns of
NASH livers.
Elevated Expression of Genes Responsible for Alcohol
Catabolism
When comparing the microarray datasets between NASH
livers and normal livers, alcohol dehydrogenase 4 (ADH4)
stands out as even more elevated than the inflammation related
g e n e sw i t ha na l m o s t4 0f o l di n c r e a s ei nN A S Hl i v e r s( T a b l e5 ,
upper panel). This observation prompted us to examine other
genes in the ADH family. Of the 7 well established members of
ADH family, ADH1A, ADH1B, ADH1C, ADH4, ADH5 and
ADH6 showed significantly elevated transcription activity in
NASH livers compared with normal livers (Table 5, upper
p a n e l ) .A D H 7a l s os e e m e dt ob eh i g h l ye l e v a t e di nN A S H
livers. However, the absolute signal for ADH7 gene transcrip-
tion is low in both liver samples and the difference is
statistically insignificant (P.0.05). This is consistent with the
fact that ADH7 is usually expressed in stomach; less in liver
[14].
Besides ADH, the liver has two additional enzymatic systems to
remove alcohol: microsomal ethanol oxidizing system (MEOS) in
endoplasmic reticulum and catalase in the peroxisomes. Signif-
icant elevation in gene transcription was observed for catalase
and cytochrome P450 2E1 (CYP2E1), the major functional
component of MEOS. Together with the augmented transcrip-
tional activities of ADH genes, these results indicated a high
demand for removing alcohols from the circulations of NASH
patients.
The immediate products from the aforementioned alcohol
oxidizing systems are aldehydes, which are more toxic than
alcohol and therefore need to be removed immediately, usually by
aldehyde dehydrogenases (ALDHs). The fact that there are many
isoforms of ALDH encoded in human genome reflects the
importance of these genes. Except ALDH3, 4, 6 and 9, all other
isoforms of ALDH were found to be transcribed significantly
higher in NASH livers compared to normal livers (Table 5, middle
panel).
Since none of the patients had any history of alcohol
consumption, these results were considered extraordinary and
therefore real-time PCR was performed to confirm the microarray
data. As ADH is the major mechanism for alcohol metabolism,
several ADH genes were targeted. Again, with GAPD as internal
reference, these ADH genes showed greater transcriptional activity
Figure 1. Quantitative RT-PCR analysis of CXCL10 in NASH
livers and normal controls (NCs). Quantitative RT-PCR analysis
were performed as described in Methods. CXCL10 and GAPD (house-
keeping gene) specific primer pairs are specified in Table 2. The
complementary DNAs prepared from NASH livers (n=6) and NCs
(n=6) were analyzed in duplicate. CXCL10 expression level of each
sample was normalized with that of GAPD. Sample means of the
CXCL10 gene expression levels were plotted with error bars indicating
the standard errors.
doi:10.1371/journal.pone.0009570.g001
Alcohol in NASH
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NASH livers, the ADH1C transcription was 12.5 times that of
normal livers. For ADH4 and ADH6, it was 30.89 and 9.81 times,
respectively. Note that these numbers showed a similar pattern
given by microarray data, in which NASH/normal=4.08
(ADH1C), 39.40 (ADH4), and 10.30 (ADH6). Significantly higher
transcriptional activities of ALDH2 and ALDH8A1 were also
observed by qRT-PCR in NASH livers compared to normal livers
(Figure 2, D and E), confirming the previously described
microarray data.
NASH Liver Did Not Exhibit Elevated Gene Transcription
for TLR4 and Related Genes
Studies with rodent models suggested that TLR4 mediated
pathway is elevated in NASH liver[15,16]. From our microarray
data, the gene transcription of TLR4 was slightly elevated in NASH
patients (NASH/normal=1.35, P,0.05). Yet the transcription of
TLR4 related genes CD14, LBP and MD-2 were not elevated
(Table 5, lower panel). In fact, a significant decrease in LBP
transcription was detected with these patients (NASH/normal=0.4,
Table 5. Comparison of gene expressions between NASH livers and normal controls: alcohol metabolism and TLR4 related genes.
{
GenBank
Accession# Gene Description
NASH Liver
(n=7)
Normal Liver
(n=4)
NASH/
Normal
{
P
value
1
NM_000667.2 alcohol dehydrogenase 1A (class I),
alpha polypeptide (ADH1A)
470.96640.68 82.50634.30 5.71 0.000
NM_000668.3 alcohol dehydrogenase IB (class I),
beta polypeptide (ADH1B)
95.00621.68 34.2369.89 2.78 0.034
NM_000669.2 alcohol dehydrogenase 1C (class I),
gamma polypeptide (ADH1C)
76.58616.72 18.7565.60 4.08 0.013
NM_000670.2 alcohol dehydrogenase 4 (class II),
pi polypeptide (ADH4)
257.14638.38 6.5362.17 39.40 0.001
NM_000671.2 alcohol dehydrogenase 5 (class III),
chi polypeptide (ADH5)
10.9561.97 2.7161.16 4.04 0.006
NM_000672.2 alcohol dehydrogenase 6 (class V) (ADH6) 36.6865.09 3.5661.14 10.30 0.000
NM_000673.2 alcohol dehydrogenase 7 (class IV),
mu or sigma polypeptide (ADH7)
0.3460.08 0.0160.11 26.96 0.053
NM_000773.2 cytochrome P450, family 2, subfamily E,
polypeptide 1 (CYP2E1)
423.85642.84 194.97650.22 2.17 0.010
NM_001752.1 catalase (CAT) 12.2762.16 0.9760.39 12.70 0.002
NM_000689.3 aldehyde dehydrogenase 1 family,
member A1 (ALDH1A1)
45.4769.70 5.6162.18 8.11 0.006
NM_003888.2 aldehyde dehydrogenase 1 family,
member A2 (ALDH1A2)
0.7060.13 0.2760.09 2.57 0.023
NM_000692.3 aldehyde dehydrogenase 1 family,
member B1 (ALDH1B1)
63.7965.52 15.0162.81 4.25 0.000
NM_000690.2 aldehyde dehydrogenase 2 family
(mitochondrial) (ALDH2)
4.4761.07 0.7160.24 6.30 0.012
NM_000695.2 aldehyde dehydrogenase 3 family,
member B2 (ALDH3B2)
0.3760.10 0.2460.09 1.55 0.354
NM_003748.2 aldehyde dehydrogenase 4 family,
member A1 (ALDH4A1)
25.8663.87 16.2562.08 1.59 0.058
NM_001080.3 aldehyde dehydrogenase 5 family,
member A1 (ALDH5A1)
3.7960.41 1.3160.45 2.89 0.004
NM_000693.1 aldehyde dehydrogenase 6 mRNA,
complete cds
0.4960.12 0.3360.08 1.48 0.280
NM_000694.1 aldehyde dehydrogenase ALDH7 8.1760.52 3.2660.21 2.51 0.000
NM_022568.2 aldehyde dehydrogenase 8 family,
member A1 (ALDH8A1)
24.4361.84 5.4660.57 4.47 0.000
NM_000696.2 aldehyde dehydrogenase 9 family,
member A1 (ALDH9A1)
89.27611.55 75.57616.01 1.18 0.513
NM_003266.2 toll-like receptor 4 (TLR4),
transcript variant 3
1.3460.12 0.9960.08 1.35 0.034
NM_000591.1 CD14 antigen (CD14) 17.4765.34 14.8566.85 1.18 0.772
NM_004139.2 lipopolysaccharide binding protein (LBP) 66.88611.71 167.76615.77 0.40 0.002
NM_015364.2 MD-2, lymphocyte antigen 96 (LY96) 5.2160.97 4.2462.77 1.23 0.758
{The gene expression levels (sample mean 6 standard error) shown were median normalized.
{Fold difference of gene expression levels (sample mean) between NASH liver tissues and normal liver controls.
1Two tailed student t test.
doi:10.1371/journal.pone.0009570.t005
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PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9570Figure 2. Quantitative RT-PCR analysis with NASH livers and NCs. Gene expression levels of (A) ADH1C, (B) ADH4, (C) ADH6, (D) ALDH2, (E)
ALDH8A1 and (F) TLR4 were examined by qRT-PCR as described in Methods. The complementary DNAs prepared from NASH livers (n=6) and NCs
(n=6) were analyzed in duplicate. PCR primer pairs are specified in Table 2. Gene expression levels of each sample were normalized with those of
GAPD. Sample means were plotted with error bars indicating the standard errors.
doi:10.1371/journal.pone.0009570.g002
Alcohol in NASH
PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9570P=0.002). Real-time PCR analysis with an overlapping but different
subgroup of NASH samples indicated that TLR4 gene transcription
was not elevated in NASH livers (Figure 2F). Therefore, the small
elevation in TLR4 gene transcription observed with microarray
analysis may not be a universal phenomenon in NASH liver.
Elevated Protein Expression of ADH1 and ADH4 in NASH
Livers
To examine the expression of ADH at protein level, Western
blot analyses were performed with the lysates made from NASH
liver biopsies (NASH, n=9; Control, n=4). As normal healthy
liver tissue from adolescent is not available, non-NASH liver
biopsies free from steatosis were used as controls. Blots were
probed with antibodies specific for ADH1 and ADH4, respective-
ly. Separate blot was also probed for b-actin as loading controls.
While all samples had similar signals for actin, NASH patients
exhibited higher expression of ADH1 and ADH4 (Figure 3A).
Quantitation of the results with NIHimage software indicated that
there were significant increases in ADH1 and ADH4 proteins in
NASH livers: for ADH1, NASH/normal control=2.8, P,0.001;
for ADH4, NASH/normal control=4.1, P,0.001 (Figure 3B).
Discussion
Liver Specific Genes, Inflammation and Fibrosis Related
Genes
Gene transcription of NASH livers was examined by a whole
genome DNA microarray and qRT-PCR techniques. Although
the sample size in the microarray analysis (NASH, n=7; NC,
n=4) is relatively small, convincing results were observed with a
larger sample size (NASH, n=6; NC, n=6) in qRT-PCR analysis.
The similar gene expression patterns detected by both techniques
testify to the reliability of the techniques and the results. We
acknowledge that the clinical information of the normal liver RNA
purchased from Admet is limited. However, we are confident that
these samples are appropriate to serve as controls, not only
because Admet guaranteed that these samples were derived from
normal healthy livers intended for transplantation, but also for the
following reasons: 1) each of the normal controls had a moderate
BMI, therefore they were not likely to have NASH (Table 1); 2)
comparison with similar gene transcription datasets of human
breast cancer showed that both the normal control RNA and
NASH RNA exhibited similar good quality, that is, liver specific
genes were highly expressed in both groups of liver tissue (Table 3);
Figure 3. Elevated expression of ADH1 and ADH4 proteins in NASH livers. (A) Western blot analyses were performed with lysates prepared
from NASH livers and NCs. The NCs were of normal BMI and free from steatosis. Separate blots were probed for ADH1, ADH4 and b-actin as these
proteins all migrate at about 43 kDa. While similar signals for actin were detected for all samples, the NASH livers exhibited stronger signals for both
ADH1 and ADH4. (B) The Western blot results were quantitated with NIHimage software. The normalized quantities of the ADH1 and ADH4 signals
were the densities of the ADH bands divided by that of the b-actin bands, respectively. The mean values for NASH and NC were plotted with error
bars representing the standard errors of the means.
doi:10.1371/journal.pone.0009570.g003
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PLoS ONE | www.plosone.org 8 March 2010 | Volume 5 | Issue 3 | e9570and 3) these normal liver samples showed lower transcription of
inflammation and fibrosis related genes as compared to NASH
liver samples, in the context of similar gene transcription for
housekeeping genes between these two groups (Table 4 and
Figure 1).
Genes Responsible for Alcohol Catabolism
Alcohol is promptly removed from circulation via three
cellular mechanisms mainly found in liver: alcohol dehydroge-
nases in the cytosol; MEOS (with cytochrome P450 2E1 as the
major component) in endoplasmic reticulum and catalase in
peroxisomes. All known ADH genes except ADH7, together
with cytochrome P450 2E1 and catalase genes, showed elevated
t r a n s c r i p t i o ni nN A S Hl i v e r s .T h ed i f f e r e n tb e h a v i o ro fA D H 7
from other alcohol oxidizing enzymes is predicted by the fact
that ADH7 is not a liver enzyme [17]. The elevated expression
for ADH1 and ADH4 at protein level were also observed in
NASH livers (NASH, n=9; NC, n=4), consistent with the
elevated mRNA levels for these genes. The significant elevation
of the activity of these enzymes indicated that 1), alcohol
concentration was elevated in the circulation and 2), it is a high
priority for NASH patients to remove alcohol from the
circulation.
All our adolescent patients claimed that they were not regular
drinkers of alcoholic beverages. We also were assured by their
parents that these adolescent patients had no access to alcoholic
beverages. Even, in the event that some of our patients did ingest
alcohol, it was certainly not consistent long-term alcohol use. In
considering other possible sources of alcohol (aspartame, fruit), we
also did a three day food record before any biopsy was performed.
We found no significant sources for alcohol.
Where did the alcohol come from? For people who do not have
access to alcoholic beverages, circulating alcohol mainly comes
from diet and intestinal bacteria. For instance, the concentration of
methanol in the human body could increase by an order of
magnitude after consumption of fruit [18]. Alcohol production by
intestinal bacteria was observed long ago in rodents and humans
[19,20]. Studies with obese ob/ob mice indicated that intestinal
bacteria are the largest source of circulating alcohol in obese
animals [10]. When intestinal bacterial growth was inhibited with
neomycin, a 50% decrease of circulating alcohol was observed in
obese mice. Based on this observation, Diehl and her colleagues
hypothesized that intestinal production of alcohol may contribute
to the genesis of non-alcoholic liver diseases [10]. Coincidently, our
microarray data provided molecular biological evidence in support
of this hypothesis. To pursue this avenue, the immediate future
directions are 1) to examine the enzymatic activities of the enzymes
related to alcohol catabolism, and 2) to measure the concentrations
of circulating alcohol in NASH patients and healthy subjects. If
these studies come to the same conclusion as the mRNA data
suggest, oral antibiotics, lactobacillus or other means of altering
colonic bacteria might be a treatment for NASH.
Our results are also consistent with two interesting discoveries.
First, it was observed that cytochrome P450 2E1 is ethanol
inducible, with a 4–10 fold increase in liver biopsies of recently
drinking subjects [21]. Second, increased P450 2E1 was detected
in NASH patients [22].
Alcohol and Steatosis
The pathomechanisms of alcohol in liver disease have been
intensively studied in alcoholic liver disease. It has long been
observed that ethanol stimulates hepatic fatty acid synthesis [23].
Figure 4. The alcohol hypothesis of non-alcoholic liver diseases. Non-alcoholic fatty liver diseases are commonly associated with obesity. In
addition to the well-known mechanisms that obesity leads to steatosis via insulin resistance, and obesity related bacteria facilitate liver inflammation,
the gene transcription data reported here support a central role for alcohol in the pathogenesis of NAFLD. Overgrowth of alcohol-producing bacteria
in the intestine of obese patients likely causes increased alcohol in the circulation, which in turn induced the expression of genes for alcohol
catabolism, including ADH and cytochrome P450 2E1. The increased activity of ADH results in the elevated level of NADH, which favors fatty acid
synthesis and opposes its break down, leading to steatosis; the elevated P450 2E1 could generate excessive ROS, a known cause for liver
inflammation.
doi:10.1371/journal.pone.0009570.g004
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reduces NAD to NADH. The increased NADH promotes fatty
acid synthesis and opposes lipid catabolism, leading to fat
accumulation in hepatocytes [23,24]. Elevated ADH level as
suggested by our microarray data strengthens the connection
between alcohol metabolism and steatosis.
Alcohol and Liver Inflammation
One possible mechanism for alcohol induced liver inflammation
begins with mucosal injury in the upper gastrointestinal tract
induced by alcohol. This leads to increased permeability for
macromolecules like LPS endotoxin. The resulting endotoxemia
would then activate TLR4 mediated signaling and culminate in
the release of pro-inflammatory cytokines (reviewed in [25]). If the
intestinal bacteria could cause elevated production of alcohol, it is
conceivable that the NASH patients may suffer from endotoxemia.
However, for all the TLR4 related genes examined (TLR4, LBP,
CD14, and MD-2), the microarray and real-time PCR analysis did
not show significant activation at the mRNA level in NASH
patients. Although more convincing conclusion awaits studies of
TLR4 signaling at the protein level in NASH patients, our data
suggest an emphasis on direct toxicity of alcohol per se.
Szabo and her colleagues reported that alcohol directly
suppressed the NF-kB activity in monocytes [26]. Their results
are in concert with a previous report that ethanol suppressed TNF
activity [27]. However, McClain’s group reported the opposite.
They found that peripheral blood monocytes from patients who
had alcoholic hepatitis have spontaneous TNF production and
enhanced LPS-stimulated TNF production [28]. Their finding was
confirmed with an in vivo experiment using rats chronically fed
alcohol [29]. Work in Nagy’s lab further revealed that ERK1/2
and Egr-1 are important mediators in elevated TNF-a production
after chronic ethanol exposure [30,31]. The reality of the ethanol
effect on TNF-a production was made clear by Kolls’ group. In a
time-series alcohol experiment, they demonstrated that acute
ethanol exposure suppressed TNF production, while long-term
treatment significantly up-regulated TNF production [32]. More
importantly, the increase in TNF production was associated with
increased generation of reactive oxygen species (ROS).
Therefore, ROS could be the important mediator between
alcohol and TNF. Alcohol is known to induce cytochrome P450,
mainly CYP2E1 [33]. Metabolism by CYP2E1 generates
superoxide and other free radicals collectively known as ROS.
There are two possible mechanisms for ROS to induce TNF
production. Firstly, ROS could serve as signaling molecules to
activate NF-kB, leading to elevated transcription of TNF-a [34];
Secondly, ROS could activate TNF-a converting enzyme, the
enzyme responsible for the processing of the transmembrane
TNF-a precursor [35].
In summary, the gene expression studies of NASH livers
revealed elevated transcription of enzymes in ALL the alcohol
metabolism pathways: ADH pathway, catalase pathway and the
MEOS pathway. Elevated expression of ADH1 and ADH4 at
protein level were also observed in NASH livers. These results
support a central role for alcohol in the development of NASH in
obese patients, as summarized in Figure 4 and for the first time,
provide molecular evidence in support of Diehl et al.’s hypothesis
that alcohol is an important mediator for the development of non-
alcoholic fatty liver diseases [10]. Our findings suggest a
mechanism that offers a single explanation for the similar
histological findings in alcoholic liver disease and NASH [3].
Our findings might provide a basis for studies on the prevention
and treatment of NASH.
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